Huaxi Bio: the plan of reducing 1% shares of shareholders Yingrui Wuyuan has been implemented

Synthetic Biology: Who Will Emerge as the Winner?

The 21st century is the century of biology. Synthetic biology is believed to be a ‘World Changing’ industry. But the potential risks like cost control and commercialization pathways are fatefully tied to the ups and downs of countless investment decisions and the destiny of the many new start-ups getting involved. We look forward to seeing an emerging ‘giant’ on the horizon of this exciting industry.

Semiconductor Company iSABers materials Completes Over $220 Million Series A++ Financing

iSABers materials (Chinese: 青禾晶元), a semiconductor materials bonding and integration technology company, announced that it has completed a Series A++ financing round totaling RMB 220 million.

Wisson Tech Releases Draco MH3000 Flexible Composite Robot

Wisson Tech(Chinese: 万勋科技), a provider of interactive service robotics solutions, recently announced the Draco MH3000 flexible composite robot, based on its proprietary flexible robotics technology (Pliabot).

Chinese Internet Tech Firm NetEase’s Revenue Rises 6.3% YoY, Reaching CNY 25 Bn in Q1 2023

NetEase continues to invest in self-research key technologies such as AI big models this quarter, with R&D investment of CNY 3.7 billion, accounting for 15% of the total revenue.

Bloomage: Injecting Biotechnology into Beauty Care

Listed on the Chinese Star Market in November 2019, Bloomage was trading at CNY 138.01 as of June 24, 2020, over 38% higher than the IPO price of CNY 100.